- You are here: Home
- Disease Models
- Oncology Models
- Humanized Mouse Models
- Humanized PBMC Mouse Models
- hPBMC-Long Term Model
Disease Models
- Oncology Models
-
Inflammation & Autoimmune Disease Models
- Rheumatoid Arthritis Models
- Glomerulonephritis Models
- Multiple Sclerosis (MS) Models
- Ocular Inflammation Models
- Sjögren's Syndrome Model
- LPS-induced Acute Lung Injury Model
- Peritonitis Models
- Passive Cutaneous Anaphylaxis Model
- Delayed-Type Hypersensitivity (DTH) Models
- Inflammatory Bowel Disease Models
- Systemic Lupus Erythematosus Animal Models
- Oral Mucositis Model
- Asthma Model
- Sepsis Model
- Psoriasis Model
- Atopic Dermatitis (AD) Model
- Scleroderma Model
- Gouty Arthritis Model
- Carrageenan-Induced Air Pouch Synovitis Model
- Carrageenan-Induced Paw Edema Model
- Experimental Autoimmune Myasthenia Gravis (EAMG) Model
- Graft-versus-host Disease (GvHD) Models
- Cardiovascular Disease Models
-
Neurological Disease Models
- Alzheimer's Disease Modeling and Assays
- Seizure Models
- Parkinson's Disease Models
- Ischemic Stroke Models
- Acute Spinal Cord Injury (ASCI) Model
- Traumatic Brain Injury (TBI) Model
- Hypoxic-Ischemic Encephalopathy (HIE) Model
- Tourette Syndrome (TS) Model
- Amyotrophic Lateral Sclerosis (ALS) Model
- Huntington's Disease (HD) Model
- Intracerebral hemorrhage (ICH) Models
- Pain Models
- Metabolic Disease Models
- Liver Disease Models
- Rare Disease Models
- Respiratory Disease Models
- Digestive Disease Models
-
Urology Disease Models
- Cisplatin-induced Nephrotoxicity Model
- Unilateral Ureteral Obstruction Model
- 5/6 Nephrectomy Model
- Renal Ischemia-Reperfusion Injury (RIRI) Model
- Diabetic Nephropathy (DN) Models
- Passive Heymann Nephritis (PHN) Model
- Adenine-Induced Chronic Kidney Disease (CKD) Model
- Kidney Stone Model
- Doxorubicin-Induced Nephropathy Model
- Orthopedic Disease Models
- Ocular Disease Models
hPBMC-Long Term Model
Creative Bioarray has revolutionized the landscape of tumor immunology and oncology drug evaluation by successfully establishing the hPBMC-Long Term Model in mice with major histocompatibility complex (MHC) molecular deficiencies. This cutting-edge model is specifically designed to address the challenges associated with assessing the efficacy and safety of immune-related therapies in a humanized model, significantly extending the experimental window and minimizing the risks of Graft-versus-Host Disease (GvHD).
Overcoming the Challenges of Graft-versus-Host Disease (GvHD)
Graft-versus-Host Disease (GvHD) presents a significant barrier in humanized PBMC mouse models, originating from the xenogeneic rejection of the host mice by transplanted human immune cells. This rejection can lead to severe outcomes, such as skin lesions, intestinal dysfunction, and damage to blood cells, drastically shortening the drug administration window and limiting the evaluation of immune-based therapies.
Innovative Solution with MHC-Deficient Mice
Our strategic approach employs mice genetically deficient in MHC molecules, effectively preventing the presentation of mouse antigens to human PBMCs and thus avoiding the onset and progression of GvHD. This method not only ensures the survival of the animals but also significantly extends the experimental window, enabling more thorough and prolonged assessments of immune-related therapies.
Our hPBMC-Long Term Model
| Animal Species | MHC Modification | Details |
| B2m-NDG | B2m Del | Extends the dosing window by 1-2 weeks. |
| B2m-NDG-hIL15 | B2m Del | Reconstructs NK Cells |
| DKO-NCG | MHC I/II Del | Better prevention of GvHD |
Key Advantages
- Reliable PBMC Reconstitution: Our advanced platform ensures consistent and dependable reconstruction of PBMCs, facilitating a robust research environment.
- Enhanced Animal Welfare: Our model significantly reduces the adverse effects of compounds that induce acute GVHD in humanized mice, promoting improved animal health and welfare.
- Robust NK Cell Reconstitution: In addition to mitigating GvHD, our platform excels in the effective reconstitution of NK cells, expanding your research capabilities.
Example Data
Fig. 1 Comprehensive analysis of hCD45+ cell in peripheral blood, body weight, body weight change and probability of survival in traditional humanized PBMC model and hPBMC long term model.
Fig. 2 Comprehensive analysis of body weight, hCD45+ cell counts and survival rate in NDG mice and B2M NDG mice.
Quotation and Ordering
Creative Bioarray boasts a vast and diverse portfolio of meticulously characterized humanized mouse models. Our dedicated team of senior scientists, specializing in these models, is poised to facilitate the timely and cost-effective evaluation of novel anti-tumor agents. Furthermore, we have established a comprehensive in vitro immunomodulation assessment service that harnesses diverse methodologies to cater to your research needs. If you are interested in our services, please feel free to contact us at any time or submit an inquiry to us directly.
For research use only. Not for any other purpose.
